{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018795","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.821288+00:00","generated_at":"2026-06-15T15:22:21.408554+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FibroGen Q1 loss $0.81; China roxadustat sales up 47%; pamrevlumab Ph3 data expected in 2023","bullets":["Net loss $76.7M ($0.81/sh) vs $63.2M ($0.68/sh) in Q1 2022.","Total revenue $36.2M, down from $60.8M (prior year included $25M milestone).","China roxadustat net product revenue $24.2M (+28% YoY); total China sales $64.1M (+47%).","Completed non-dilutive term loan facility of up to $150M with Morgan Stanley Tactical Value.","Topline data from four Phase 3 trials (pamrevlumab in DMD, IPF, LAPC; roxadustat in CIA) expected through 3Q 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018795","json":"https://secwatch.observer/filing/0000950170-23-018795.json","markdown":"https://secwatch.observer/filing/0000950170-23-018795.md","text":"https://secwatch.observer/filing/0000950170-23-018795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017023018795/0000950170-23-018795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017023018795/fgen-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T15:22:21.408554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f06d59564ad35efd78e11f4408ad76007ddd0d7f","claim":"KYNTRA BIO, INC. reported financial results for the first quarter 2023.","evidence_excerpt":"On May 8, 2023, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017023018795/0000950170-23-018795-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}